ITGB1+ EVs are involved in ECM interactions and metastatic niche formation [73,74], while CD44+ EVs are linked to tumor recurrence and therapy resistance in GBM, suggesting their role as biomarkers for aggressive tumor subtypes [42,75]. Here, CD44 is linked to glioblastoma.